CHICAGO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- COUR Pharmaceuticals, a clinical-stage biotechnology company focused on the development of first-in-class, disease modifying therapies designed to induce ...
CHICAGO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies to treat autoimmune diseases, today announced that ...
Cour Pharmaceuticals, the Chicago-based clinical-stage biotechnology company, says its first patient has been dosed in the phase 1b/2a clinical trial of a treatment that it hopes will address ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback